Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis
Unusual Whales The trial was assessed by the Independent Data Monitoring Committee (IDMC) and found to be unlikely to achieve the primary endpoint.
